Compare Illumina, Inc. (ILMN) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Vanguard Short Term Corporate Bond ETF — how do they compare? Illumina, Inc. trades at $265.87 (market cap $39.95B), while Vanguard Short Term Corporate Bond ETF trades at $77.34 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| ILMN | VCSH | |
|---|---|---|
Market Cap | $39.95B | $51.90B |
Volume | 3,169,503 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $293.69 | $80.20 |
52-Week Low | $91.00 | $77.03 |
Typical Hold Time | 83 Days | 52 Days |
Enterprise Value | $41.31B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
VCSH, the Vanguard Short-Term Corporate Bond ETF, trades at $77.27 with a slight 0.08% daily gain. Technical indicators show a bearish trend from moving averages, though oscillators are neutral. The ETF offers a competitive yield and low expense ratio, but faces headwinds from tight credit spreads and a cautious market outlook. Recent news highlights its role as a stable income alternative to CDs or stable value funds, with institutional activity showing mixed positioning.
The outlook for VCSH is neutral with limited upside due to unattractive entry points and constrained credit spreads. Its short duration minimizes interest rate risk, but yield advantages over peers may narrow. Key risks include corporate credit deterioration and Fed policy shifts. Investors seeking short-term, high-quality bond exposure may find value, but current levels offer modest total return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
